AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38754876 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic factors assessed at 1-month post-radiotherapy for subjective UL function (QuickDASH) at 6 months post-surgery.
Number of subjects: 250
Study 38754876 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective measure for UL function (accelerometry) and a composite score of subjective and objective UL function.
Number of subjects: 250
Study 38754877 — intervention group
Group type: EXPERIMENTAL
Intervention: Living With the Sun (LWS) educational programme
Number of subjects: 1780
Study 38754877 — intervention group
Group type: EXPERIMENTAL
Intervention: Living With the Sun (LWS) + Mission Soleil Réunion's sun protection awareness programme
Number of subjects: 1780
Study 38754877 — intervention group
Group type: EXPERIMENTAL
Intervention: Living With the Sun (LWS) + Mission Soleil Réunion's sun protection awareness programme + distribution of hats, sunglasses, and sun creams
Number of subjects: 1780
Study 38754877 — intervention group
Group type: COMPARATOR
Intervention: Control arm without proposed intervention
Number of subjects: 1780
Study 38754880 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT V/Q
Number of subjects: 3672
Study 38754880 — intervention group
Group type: COMPARATOR
Intervention: CTPA
Number of subjects: 3672
Study 38754880 — intervention group
Group type: COMPARATOR
Intervention: Planar V/Q
Number of subjects: 3672
Study 38754881 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel index tests for diagnosis at baseline
Number of subjects: 800
Study 38754881 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic markers for severe IBD
Number of subjects: 800
Study 38754888 — intervention group
Group type: EXPERIMENTAL
Intervention: GFAP and UCH-L1 biomarkers used separately and in combination
Number of subjects: 2880
Study 38754888 — intervention group
Group type: EXPERIMENTAL
Intervention: GFAP and UCH-L1 biomarkers
Number of subjects: 2880
Study 38754891 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercise of 10,000-15,000 steps per day for 3-4 weeks prior to craniotomy
Number of subjects: 160
Study 38754891 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment
Number of subjects: 160
Study 38754891 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercise
Number of subjects: 160
Study 38754979 — intervention group
Group type: EXPERIMENTAL
Intervention: CR plus EX
Number of subjects: 104
Study 38754979 — intervention group
Group type: EXPERIMENTAL
Intervention: CR plus EX-S
Number of subjects: 104
Study 38754979 — intervention group
Group type: COMPARATOR
Intervention: CR-S
Number of subjects: 104
Study 38754979 — intervention group
Group type: COMPARATOR
Intervention: EX plus sham CR (CR-S)
Number of subjects: 104
Study 38754989 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine and 1% lidocaine
Number of subjects: 40
Study 38754989 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 40
Study 38754991 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral anterior quadratus lumborum block with 30 mL ropivacaine 0.75%
Number of subjects: 20
Study 38754991 — intervention group
Group type: COMPARATOR
Intervention: Placebo block
Number of subjects: 20
Study 38755096 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg every 21 days with investigator-selected chemotherapy (carboplatin plus gemcitabine or capecitabine monotherapy) until disease progression or unacceptable toxicity.
Number of subjects: 354
Study 38755096 — intervention group
Group type: COMPARATOR
Intervention: Placebo with investigator-selected chemotherapy (carboplatin plus gemcitabine or capecitabine monotherapy) until disease progression or unacceptable toxicity.
Number of subjects: 354
Study 38755096 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg every 21 days with investigator-selected chemotherapy.
Number of subjects: 354
Study 38755096 — intervention group
Group type: COMPARATOR
Intervention: Placebo with investigator-selected chemotherapy.
Number of subjects: 354
Study 38755096 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms (Atezolizumab and Placebo) with investigator-selected chemotherapy.
Number of subjects: 354
Study 38755195 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 1002
Study 38755195 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 1002
Study 38755201 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin supplementation for 6 months
Number of subjects: 46
Study 38755201 — intervention group
Group type: COMPARATOR
Intervention: Bifidobacterium + inulin treatment in vitro
Number of subjects: 46
Study 38755568 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab, 140 mg every four weeks for 16 weeks (post-treatment)
Number of subjects: 36
Study 38755568 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab
Number of subjects: 36
Study 38755568 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline levels of hsa-miR-34a-5p and hsa-miR-382-5p in women with CM
Number of subjects: 36
Study 38755568 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up levels of hsa-miR-34a-5p and hsa-miR-382-5p in women with CM
Number of subjects: 36
Study 38755582 — intervention group
Group type: EXPERIMENTAL
Intervention: Needs-tailored recovery program for six months
Number of subjects: 164
Study 38755582 — intervention group
Group type: COMPARATOR
Intervention: Traditional homecare
Number of subjects: 164
Study 38755585 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib maintenance therapy
Number of subjects: 225
Study 38755688 — intervention group
Group type: EXPERIMENTAL
Intervention: BrainHQ
Number of subjects: 0
Study 38755688 — intervention group
Group type: EXPERIMENTAL
Intervention: BrainHQ + PASC-Cognitive Recovery
Number of subjects: 0
Study 38755688 — intervention group
Group type: EXPERIMENTAL
Intervention: BrainHQ + tDCS-active
Number of subjects: 0
Study 38755688 — intervention group
Group type: EXPERIMENTAL
Intervention: BrainHQ + tDCS-sham
Number of subjects: 0
Study 38755688 — intervention group
Group type: COMPARATOR
Intervention: Active Comparator
Number of subjects: 0
Study 38755699 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 25
Study 38755699 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 25
Study 38755699 — intervention group
Group type: COMPARATOR
Intervention: Both treatment groups
Number of subjects: 25
Study 38755706 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-powered digital DPP (ai-DPP)
Number of subjects: 368
Study 38755706 — intervention group
Group type: COMPARATOR
Intervention: Human coach-based DPP (h-DPP)
Number of subjects: 368
Study 38755709 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of apixaban twice a day for the first 3 months and 100 mg of acetylsalicylic acid thereafter
Number of subjects: 0
Study 38755709 — intervention group
Group type: COMPARATOR
Intervention: 100 mg of acetylsalicylic acid once a day, indefinitely
Number of subjects: 0
Study 38755732 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver stiffness measurement in addition to usual care
Number of subjects: 40
Study 38755732 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study 38756107 — intervention group
Group type: EXPERIMENTAL
Intervention: msRDN
Number of subjects: 220
Study 38756107 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 220
Study 38756610 — intervention group
Group type: EXPERIMENTAL
Intervention: Unisabana-HERONS ventilator
Number of subjects: 5
Study 38756738 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation treatment
Number of subjects: 113
Study 38756745 — intervention group
Group type: EXPERIMENTAL
Intervention: OUD-CDS (Clinical Decision Support Tool)
Number of subjects: 305
Study 38756745 — intervention group
Group type: COMPARATOR
Intervention: Patient requests for buprenorphine
Number of subjects: 305
Study 38756888 — intervention group
Group type: EXPERIMENTAL
Intervention: I'm an Active Hero (IAAH) intervention
Number of subjects: 143
Study 38756888 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 143
Study 38757134 — intervention group
Group type: EXPERIMENTAL
Intervention: active tDCS (n=25)
Number of subjects: 50
Study 38757134 — intervention group
Group type: COMPARATOR
Intervention: sham tDCS (n=25)
Number of subjects: 50
Study 38757184 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower bilateral amygdala activation for sad faces
Number of subjects: 45
Study 38757184 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower amygdala response to negative facial emotions
Number of subjects: 45
Study 38757485 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery alone for low-risk patients (n=80)
Number of subjects: 99
Study 38757485 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide/doxorubicin and radiotherapy for intermediate-/high-risk patients (n=19)
Number of subjects: 99
Study 38757485 — intervention group
Group type: COMPARATOR
Intervention: Had the FNCLCC grading system been used
Number of subjects: 99
Study 38757664 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Application combined with SWalker
Number of subjects: 0
Study 38757713 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT)
Number of subjects: 2451
Study 38757713 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 2451
Study 38757714 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention in the clinic waiting room
Number of subjects: 0
Study 38757714 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38757854 — intervention group
Group type: EXPERIMENTAL
Intervention: Education group (EG) with occlusal splint (OS) and musculoskeletal physiotherapy (MPT)
Number of subjects: 62
Study 38757854 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with occlusal splint (OS) and education only
Number of subjects: 62
Study 38757982 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosmanogepix (FMGX) with strong CYP3A4 inhibitor itraconazole
Number of subjects: 0
Study 38757982 — intervention group
Group type: COMPARATOR
Intervention: Fosmanogepix (FMGX)
Number of subjects: 0
Study 38758205 — intervention group
Group type: EXPERIMENTAL
Intervention: DTG/FTC/TAF
Number of subjects: 29
Study 38758205 — intervention group
Group type: COMPARATOR
Intervention: DTG/3TC/TDF
Number of subjects: 29
Study 38758212 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Insulin Delivery
Number of subjects: 0
Study 38758212 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38758370 — intervention group
Group type: EXPERIMENTAL
Intervention: SV2A PET-tracer
Number of subjects: 11
Study 38758400 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent control of renal pelvic pressure (RPP) at -5 mmHg
Number of subjects: 73
Study 38758400 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent control of renal pelvic pressure (RPP) at 0 mmHg
Number of subjects: 73
Study 38758400 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent control of renal pelvic pressure (RPP) at 5 mmHg
Number of subjects: 73
Study 38758400 — intervention group
Group type: COMPARATOR
Intervention: Conventional flexible ureteroscopy with uncontrolled pressure
Number of subjects: 73
Study 38758433 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient-boosted tree model
Number of subjects: 10320
Study 38758433 — intervention group
Group type: COMPARATOR
Intervention: Logistic regression model
Number of subjects: 10320
Study 38758433 — intervention group
Group type: COMPARATOR
Intervention: Deep learning model
Number of subjects: 10320
Study 38758433 — intervention group
Group type: COMPARATOR
Intervention: Decision tree model
Number of subjects: 10320
Study 38758433 — intervention group
Group type: COMPARATOR
Intervention: Random forest model
Number of subjects: 10320
Study 38758503 — intervention group
Group type: EXPERIMENTAL
Intervention: AlphaWave
Number of subjects: 30
Study 38758557 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted ventilation for 120 seconds followed by cord clamping
Number of subjects: 570
Study 38758557 — intervention group
Group type: COMPARATOR
Intervention: Delayed cord clamping for 30 to 60 seconds followed by standard resuscitation
Number of subjects: 570
Study 38758557 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted ventilation for 120 seconds in not-breathing-well cohort
Number of subjects: 570
Study 38758557 — intervention group
Group type: COMPARATOR
Intervention: Delayed cord clamping for 30 to 60 seconds in not-breathing-well cohort
Number of subjects: 570
Study 38758581 — intervention group
Group type: EXPERIMENTAL
Intervention: PREVENT (digital health tool)
Number of subjects: 36
Study 38758581 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 36
Study 38758583 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly text-based monitoring of 8 PROs plus continuous step count monitoring via Fitbit
Number of subjects: 57
Study 38758639 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated HRF segmentation using SD-OCT
Number of subjects: 1527
Study 38758815 — intervention group
Group type: EXPERIMENTAL
Intervention: GZ17-6.02 at 375 mg PO BID
Number of subjects: 0
Study 38758815 — intervention group
Group type: EXPERIMENTAL
Intervention: GZ17-6.02 in combination with doxorubicin or ERBB family inhibitors
Number of subjects: 0
Study 38758815 — intervention group
Group type: EXPERIMENTAL
Intervention: GZ17-6.02
Number of subjects: 0
Study 38758967 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-guided focussed ultrasound-stimulated microbubble (MRgFUS-MB) treatment
Number of subjects: 18
Study 38759121 — intervention group
Group type: EXPERIMENTAL
Intervention: Two fractionation schedules
Number of subjects: 0
Study 38759121 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38759278 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytology
Number of subjects: 3180
Study 38759278 — intervention group
Group type: EXPERIMENTAL
Intervention: p16/ki67 dual staining (DS)
Number of subjects: 3180
Study 38759278 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year HPV retesting
Number of subjects: 3180
Study 38759278 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-year retesting for low-risk group
Number of subjects: 3180
Study 38759431 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive control (parameters of cognitive control)
Number of subjects: 424
Study 38759431 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood Trauma Questionnaire (CTQ)
Number of subjects: 424
Study 38759431 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Inventory for Chronic Stress (TICS)
Number of subjects: 424
Study 38759431 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck's Depression Inventory (BDI)
Number of subjects: 424
Study 38759581 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone or Amiodarone infusion
Number of subjects: 209
Study 38759667 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted EXTREME regimen (six cycles of fluorouracil 4000 mg/m²)
Number of subjects: 85
Study 38759667 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted EXTREME regimen
Number of subjects: 85
Study 38759667 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab during maintenance phase
Number of subjects: 85
Study 38759886 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily egg consumption for 6 months
Number of subjects: 3051
Study 38759886 — intervention group
Group type: COMPARATOR
Intervention: Control (no egg consumption)
Number of subjects: 3051
Study 38759907 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT-guided PCI
Number of subjects: 1493
Study 38759907 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 1493
Study 38759905 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricuspid transcatheter edge-to-edge repair (TEER) with the TriClip system
Number of subjects: 511
Study 38759904 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete anatomical revascularization
Number of subjects: 670
Study 38759904 — intervention group
Group type: EXPERIMENTAL
Intervention: Viability-guided revascularization
Number of subjects: 670
Study 38759904 — intervention group
Group type: COMPARATOR
Intervention: Incomplete revascularization
Number of subjects: 670
Study 38759904 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 670
Study 38759910 — intervention group
Group type: EXPERIMENTAL
Intervention: LINKED-HEARTS intervention arm
Number of subjects: 428
Study 38759910 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC) arm
Number of subjects: 428
Study 38760029 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy
Number of subjects: 0
Study 38760029 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended pleurectomy decortication surgery
Number of subjects: 0
Study 38760029 — intervention group
Group type: EXPERIMENTAL
Intervention: Bespoke support strategies
Number of subjects: 0
Study 38760029 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruiter feedback and training
Number of subjects: 0
Study 38760029 — intervention group
Group type: EXPERIMENTAL
Intervention: QuinteT Recruitment Intervention
Number of subjects: 0
Study 38760050 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-emptive pharmacogenomics (PGx) testing for actionable PGx variants
Number of subjects: 440
Study 38760050 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 440
Study 38760075 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-5T4
Number of subjects: 94
Study 38760075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 38760081 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy compressive taping for 7 days
Number of subjects: 124
Study 38760081 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy compressive taping
Number of subjects: 124
Study 38760098 — intervention group
Group type: EXPERIMENTAL
Intervention: Inebilizumab (300 mg) administered intravenously on days 1 and 15 during the randomised period and continued every 6 months for a minimum of 2 years in the open-label period.
Number of subjects: 231
Study 38760098 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered on days 1 and 15 during the randomised period.
Number of subjects: 231
Study 38760478 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive thinking
Number of subjects: 482
Study 38760478 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 482
Study 38760478 — intervention group
Group type: EXPERIMENTAL
Intervention: Good sleep quality
Number of subjects: 482
Study 38760478 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance coping behaviors
Number of subjects: 482
Study 38760478 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep disturbance
Number of subjects: 482
Study 38760478 — intervention group
Group type: EXPERIMENTAL
Intervention: OSCE performance
Number of subjects: 482
Study 38760584 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-tip catheter with dual pulsed field and radiofrequency energies
Number of subjects: 420
Study 38760584 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiofrequency ablation system
Number of subjects: 420
Study 38760589 — intervention group
Group type: EXPERIMENTAL
Intervention: p75 neurotrophin receptor modulation
Number of subjects: 0
Study 38760589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38760702 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam
Number of subjects: 330
Study 38760702 — intervention group
Group type: COMPARATOR
Intervention: Real-world midazolam
Number of subjects: 330
Study 38760702 — intervention group
Group type: COMPARATOR
Intervention: On-label midazolam
Number of subjects: 330
Study 38760747 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional fixed appliances (Group A)
Number of subjects: 60
Study 38760747 — intervention group
Group type: COMPARATOR
Intervention: Clear aligners (Group B)
Number of subjects: 60
Study 38760758 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing and rinsing with Listerine® Cool Mint® Antiseptic (BA)
Number of subjects: 286
Study 38760758 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing and rinsing with Listerine® Cool Mint® Zero (BZ)
Number of subjects: 286
Study 38760758 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing, flossing, and rinsing with Listerine® Cool Mint® Zero (BFZ)
Number of subjects: 286
Study 38760758 — intervention group
Group type: COMPARATOR
Intervention: Brushing only (B)
Number of subjects: 286
Study 38760758 — intervention group
Group type: COMPARATOR
Intervention: Brushing and flossing (BF)
Number of subjects: 286
Study 38760800 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote family education and support program (four, 150 min weekly group sessions) for parents plus treatment-as-usual for patients
Number of subjects: 70
Study 38760800 — intervention group
Group type: COMPARATOR
Intervention: Waiting for the control condition (parents will wait to start the program for 8 weeks) plus treatment-as-usual for patients
Number of subjects: 70
Study 38760800 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote family education and support program
Number of subjects: 70
Study 38760804 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. citicoline (0.5 mg/kg, 2.5 mg/kg, or 5 mg/kg every 12 hours for 5 days)
Number of subjects: 60
Study 38760804 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly detailed in the abstract)
Number of subjects: 60
Study 38760833 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized reduction of non-resuscitation fluids
Number of subjects: 92
Study 38760833 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 92
Study 38760833 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause mortality
Number of subjects: 92
Study 38760833 — intervention group
Group type: EXPERIMENTAL
Intervention: Days alive and free of mechanical ventilation
Number of subjects: 92
Study 38760833 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute kidney injury or ischemic events in the ICU within 90 days
Number of subjects: 92
Study 38760833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognition at six months
Number of subjects: 92
Study 38760833 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life at six months
Number of subjects: 92